Novel design principle validated: Glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent
Authors:
- László SomsákLászló Somsák
- Veronika NagyVNVeronika Nagy
- Sébastien VidalSVSébastien Vidal
- Katalin CzifrákKCKatalin Czifrák
- Eszter BerzsényiEBEszter Berzsényi
- Jean-Pierre PralyJPJean-Pierre Praly
Open Access
- 1 October 2008
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (20) , 5680-5683
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- New hepatic targets for glycaemic control in diabetesBest Practice & Research Clinical Endocrinology & Metabolism, 2007
- Glycogen phosphorylase inhibition as a therapeutic target: a review of the recent patent literatureExpert Opinion on Therapeutic Patents, 2006
- Chemistry and Biochemistry of Type 2 DiabetesChemical Reviews, 2004
- Hepatic glucose metabolism in humans—its role in health and diseaseBest Practice & Research Clinical Endocrinology & Metabolism, 2003
- Prospects for Pharmacologic Inhibition of Hepatic Glucose ProductionCurrent Medicinal Chemistry, 2003
- Glycogen Phosphorylase as a Molecular Target for Type 2 Diabetes TherapyCurrent Protein & Peptide Science, 2002
- Hepatic glucose production: therapeutic target in type 2 diabetes?Diabetes, Obesity and Metabolism, 2002
- New drug targets for type 2 diabetes and the metabolic syndromeNature, 2001
- Global and societal implications of the diabetes epidemicNature, 2001
- Glycogen phosphorylase: control by phosphorylation and allosteric effectorsThe FASEB Journal, 1992